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Diabetes mellitus is the most common metabolic disorder characterized by hyperglycemia and associated malfunctions of the
metabolism of carbohydrates, proteins, and lipids. There is increasing evidence of a relationship between diabetes and vascular
dementia. Interestingly, hyperglycemia-linked neuroinflammation in the central nervous system is considered to play a key role
during vascular dementia in diabetic patients. However, the mechanisms responsible for the relationship between hyperglycemia
and neuroinflammation is not clearly understood. Diabetes-induced alternations in the blood-brain barrier permit high glucose
influx into the brain cells via glucose transporters and promote oxidative stress through overproduction of reactive oxygen
species. Despite many studies demonstrating a link between oxidative stress and mitochondrial dysfunction, the relationship
between mitochondrial dysfunction and neuron inflammation during hyperglycemia remains to be established. In this review,
we will focus on diabetes-induced changes in the central nervous system and the role of mitochondrial heat shock protein 60
(HSP60) as an initiator of oxidative stress and potential modulator of neuroinflammation. We suggest that oxidative stress-
mediated mitochondrial dysfunction stimulates the upregulation of mitochondrial heat shock protein 60 (HSP60) and ultimately
initiates inflammatory pathways by activating pattern recognition receptors. HSP60 also could be a focal point in the
development of a biomarker of neuroinflammation as HSP60 is known to be significantly elevated in diabetic patients.
Interestingly, extracellular secretion of HSP60 via exosomes suggests that inflammation could spread to neighboring astrocytes
by activating pattern recognition receptors of astrocytes via neuronal exosomes containing HSP60. A mechanism for linking
neuron and astrocyte inflammation will provide new therapeutic approaches to modulate neuroinflammation and therefore
potentially ameliorate the cognitive impairment in diabetic brains associated with vascular dementia.
1. Diabetes Mellitus
Diabetes mellitus is an endocrine disease characterized by
hyperglycemia which occurs as a result of the inability of
the pancreas to secrete insulin, defects in insulin action, or
both [1]. Diabetes is classified into three main categories as
type 1, type 2, and gestational diabetes based on the clinical
manifestation [2]. Type 1 diabetes is characterized by hyper-
glycemia due to the cellular-mediated autoimmune destruc-
tion of pancreatic β cells which leads to the production of
less insulin. In contrast, type 2 diabetes is described as the
incapability of the body to effectively respond to insulin
which leads to insulin resistance and relative insulin defi-
ciency. Gestational diabetes is explained as any degree of
glucose intolerance that is recognized during pregnancy
which resolves on delivery of the placenta [3]. Hyperglyce-
mia results in both microvascular and macrovascular com-
plications which lead to long-term failure of various organs
[4]. Oxidative stress-induced events are considered the most
important unifying pathogenic factor that is responsible for
the initiation and progression of diabetic complications [5].
Hyperglycemia-induced oxidative stress is characterized by
the production of reactive oxygen species (ROS) via multiple
pathways such as glucose autooxidation, increased metabolic
flux of the polyol (sorbitol) pathway, increased production
of advanced glycation end products (AGE), activation of
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2. Vascular Complications of
Diabetes (Atherosclerosis)
Atherosclerosis is the formation of cholesterol plaque in the
walls of arteries and leads to obstruction of normal blood
flow [6]. Hyperglycemia is responsible for many alternations
in vascular endothelial and smooth muscle tissues and initi-
ates local inflammation in the vascular wall [7]. Injured vascu-
lar endothelial cells stimulate the adhesion of monocytes, and
T lymphocytes infiltrate into the vascular intima through vas-
cular walls. Subsequently, monocytes penetrate the suben-
dothelial space, differentiate, and mature into macrophages
that release cytokines. In diabetic patients, hyperglycemic
condition results in the elevation of apolipoproteins in sys-
temic circulation. High levels of low-density lipoproteins
(LDL) facilitate the infiltration of LDL cholesterol molecules
into subendothelial space and retention in the intima where
it can be oxidized. Hyperglycemia also leads to the formation
of several reactive oxygen species capable of promoting LDL
oxidation [8]. Consequently, arterial macrophages can take
up oxidized lipoproteins and stimulate the formation of foam
cell which ultimately lead to atherogenesis [9]. Ritarwan and
coworkers have successfully modeled the occurrence of ath-
erosclerosis in streptozotocin-treated mice with increasing
blood glucose and cholesterol level [10].
3. Diabetes-Induced Complications in the
Central Nervous System
3.1. Diabetic Brain. The brain primarily utilizes glucose as a
source of energy, which enters the brain through glucose
transporters (GLUT-1) by crossing the blood-brain barrier
[11]. The blood-brain barrier (BBB) is the protective gate of
the central nervous system which prevents the entrance of
potentially harmful substance. Endothelial cells connecting
with tight junctions (TJ) construct the fundamental structure
of the BBB. Pericytes and astrocytes contribute to the forma-
tion of basement membrane of the BBB [12]. Intercellular
proteins such as claudin, occludin, and junctional adhesion
molecules (JAMS) are responsible for producing the endo-
thelial tight junctions which act as a filter for protein and cells
across the vessel wall [13]. BBB regulates the transport of
important molecules including glucose to maintain the brain
homeostasis. Hyperglycemic condition is known to cause
BBB impairments in diabetic patients which lead to the path-
ogenesis of various brain vascular complications [14]. In the
diabetic patients, hyperglycemia facilitates a high respiration
rate in pericytes and astrocytes which leads to high ROS pro-
duction and oxidative stress [15]. Enhanced ROS production
stimulates the upregulation of inflammatory cytokines and
activation of the NF-κB pathway which promote BBB leak-
ages [16]. In addition, high concentration of ROS also
inhibits the folding of gap junction proteins and disturbs
astrocyte communication pathways [17]. Eventually, these
impairments lead to inflammation-induced BBB opening
and facilitate the entrance of high glucose influx into the cen-
tral nervous system [17, 18].
3.2. Hyperglycemia-Induced ROS Production in the Neuron.
The brain is one of the most vulnerable organs to oxidative
stress [19]. Hyperglycemia-induced overproduction of ROS
is considered as a key pathological factor in neuronal dys-
function which leads to cognitive impairments [20]. Prolong
exposure to high glucose level stimulates various irregular
glucose metabolic pathways [21]. In hyperglycemia, excess
glucose generates metabolites in the polyol pathway and
autooxidation of glucose which leads to the formation of
advanced glycation end products [5]. In the polyol pathway,
glucose is reduced to sorbitol, which is subsequently oxidized
to fructose in the presence of aldose reductase [22]. These
reactions oxidize NADPH to NADP+ as well as NADH from
NAD+. Therefore, activation of the polyol pathway results in
low concentration of NADPH and oxidized NAD+ which are
important cofactors in redox reactions [22]. Elevated glucose
concentration also undergoes nonenzymatic glycation reac-
tions with primary amino acids and forms stable covalent
products called advanced glycation end products (AGE).
Subsequently, AGEs bind to a cell surface receptor known
as receptor for AGE (RAGE) and induce excess production
of ROS [23]. High concentration of ROS is considered to be
hazardous for neuronal development and function. It initi-
ates the misfolding of proteins in neuronal mitochondria
[24]. Overproduction of ROS in the central nervous system
also enhances tissue damage and disrupts neuronal regener-
ation [25].
3.3. Oxidative Stress-Induced Mitochondrial Dysfunction in
the Neuron. The mitochondrion is the major organelle in
the ATP production through electron transport chain and
oxidative phosphorylation [26]. Neurons have high energy
demands, and neuronal mitochondria supply constant
energy for the adequate function of the neuron cells [27].
Brain neurons are mostly vulnerable to oxidative stress due
to high consumption of oxygen, high concentration of mem-
brane polyunsaturated fatty acids, and moderate antioxidant
defense mechanisms [28]. Recent studies have demonstrated
the critical role of the mitochondria in the progression of
hyperglycemia-induced neuronal damage. Impairment of
the mitochondrial function is a key feature of many neurode-
generative diseases [29]. Mitochondrial oxidative stress initi-
ates a series of processes including mitochondrial DNA
mutation, dysfunction in respiratory chain activity, detri-
mental changes in mitochondrial membranes, and defects
in Ca2+ homeostasis [30]. In vitro diabetic neuropathy
models have shown that excess ROS damages the mitochon-
drial electron transport chain, cellular proteins, lipids, and
DNA and subsequently interferes with the normal mitochon-
drial function in dorsal root ganglion neurons [31]. Mito-
chondrial DNA is particularly susceptible to oxidative stress
as the mitochondrial DNA lacks histone proteins and con-
tains inefficient DNA repair systems [32]. However, mito-
chondria do contain a family of proteins (molecular stress
proteins) which combat mitochondrial protein misfolding
during oxidative stress.
3.4. Role of Molecular Stress Proteins during Mitochondrial
Dysfunction. Mitochondrial stress is characterized by the
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accumulation of unfolded proteins which ultimately lead to
impaired mitochondrial function [33]. It is evident that
hyperglycemia-induced alternations in mitochondrial elec-
tron transport are a key causative factor for mitochondrial
dysfunction [34]. Molecular stress proteins are a group of
proteins which enable mitochondria to respond to stress-
induced protein misfolding [35]. Heat shock protein 60
(HSP60) is one such molecular stress protein that is
expressed in both prokaryotes and eukaryotic cells [36].
HSP60 is synthesized in the cytosol as a response of cellular
stress and subsequently targeted the mitochondria, where it
contributes to mitochondrial protein homeostasis [37].
HSP60 assists mitochondrial protein folding as well as dena-
tured polypeptides in an ATP-dependent manner with the
cochaperon HSP10 [38]. Recent studies have discovered that
HSP60 knockdown decreases mitochondrial activity by
increasing cell proliferation [39]. Afroz and coworkers have
also revealed the interaction of HSP60 with mitochondrial
proteins which promotes deregulation of mitochondrial
function during infections [40]. Interestingly, HSP60 can also
be translocated to the cell surface and secreted into the extra-
cellular environment, where it can importantly function as an
inflammatory regulator.
4. Immune Regulatory Action of Heat Shock
Protein 60
4.1. Innate Immune System and CNS Inflammation. The
immune system of the body consists of antigen-specific adap-
tive immune response as well as innate immune response
[41]. The innate immune system is essentially protecting
the body from viruses, bacteria, parasites, and other foreign
particles by limiting their ability to spread and move
throughout the body [42]. The innate immune system
operates in the body mainly through pattern recognition
receptors (PRRs). Pattern recognition receptors (PRRs) are
proteins that enable to recognize molecules frequently found
in pathogens which are called as pathogen-associated molec-
ular patterns (PAMPs) or molecules released by damaged
cells which are known as damage-associated molecular pat-
terns (DAMPs) [43]. Despite PRR being found in the cytosol,
cellular, and endosomal membranes as well as in an extracel-
lular environment, secreted forms can be found in the
bloodstream and interstitial fluids [44]. PRR can be divided
into subfamilies such as Toll-like receptors (TLRs), C-type
lectin receptors (CLRs), NOD-like receptors (NLRs), RIG-
I-like receptors (RLRs), and AIM2-like receptor (ALR)
[45]. These receptors activate innate immune responses by
producing inflammatory cytokines, type I interferon, and
other mediators. Among these families, the TLR families
are well-characterized receptors comprising ten members
(TLR1–TLR10) in human [46]. TLRs locate in the cell sur-
face or in intracellular compartments as endosome, lyso-
some, ER and specific lipids, proteins, and nucleic acids
[47]. Inflammasomes are also a group of pattern recognition
receptors mainly NLRs that enable the activation of the
secretion of inflammatory mediators [48]. It is evident that
inflammasomes are necessary in the recognition of PAMPs
or DAMPS by Toll-like receptors. Inflammasomes can also
be activated by ROS, lysosomal damage, and cytosolic K+ flux
[48]. Activation of PRR subsequently leads to inflammation
which provides a broad spectrum of defense mechanisms
against invasion and distribution of foreign pathogens, tissue
injury, and many irritants. However, chronic and uncon-
trolled inflammation often leads to tissue damage through
overzealous inflammatory responses.
Hyperglycemia results in persistent cellular stress in
neurons which leads to chronic inflammatory changes.
Hyperglycemia-induced reactive oxygen species and alter-
ations in the redox equilibrium which produce oxidative stress
play a vital role in the stimulation of immune cells in the dia-
betic brain [49]. Oxidative stress in the CNS is considered a
critical step in stimulating CNS inflammatory pathways [50].
It is evident that overproduction of ROS enables the activation
TLRs and inflammasomes in the CNS leading to the activation
of inflammatory pathways. The activation of transcription fac-
tor, nuclear factor-kappa B (NF-κB), has been identified as a
key for neural dysfunction in many in vivo models ([51];
Wen et al., 2018). It also stimulates inflammation-induced dis-
ruption of synaptic signaling which leads to impairments in
learning and memory in diabetic individuals.
4.2. HSP60 in Neuroinflammation. Neuroinflammation is a
result of an innate immune response in the CNS. Astrocytes,
microglia, and neurons play a vital role in maintaining tissue
homeostasis and contribute to an inflammatory response
through cytokine secretion [52]. Many recent studies have
provided the link between mitochondrial stress and inflam-
mation through HSP60 which can stimulate inflammatory
mediators [53]. Numerous in vivo models have shown that
HSP60 has both beneficial immune regulatory functions
and harmful inflammatory properties. Earlier, it was recog-
nized that HSP60 is an intracellular chaperon protein, but
later, HSP60 has been identified as an important extracellular
antigen in the human body [54]. Now, it is clear that HSP60
can act as an inflammatory danger signal in the innate
immune responses [55]. Toll-like receptors are mostly consid-
ered a sensor for PAMs by playing an important role in the
innate immune responses. Interestingly, reports have demon-
strated that mammalian HSP60 can interact with TLRs by
providing a nonpathogen-derived ligand for TLR [56]. Inter-
action of HSP60 and TLR stimulates inflammatory signaling
cascade which ultimately leads to the production of proin-
flammatory mediators such as TNF-α, IL-1β, IL-6, and IL-8
[56]. Tian et al. have discovered that the extracellular HSP60
stimulates inflammation through activating and upregulating
TLR-2 and TLR-4 in cardiomyocytes [57]. It is postulated that
extracellular upregulation of HSP60 in neuron cells may act as
a potential mediator for neuroinflammation. Rosenberger and
coworkers have extensively studied the interaction of HSP60
with TLRs and impact on the brain cell with in vivo wild-
type mouse model [58]. Their findings have revealed that
intrathecal administration of HSP60 can mediate neuroin-
flammation in neuron and glial cells through Toll-like recep-
tor 4 and 2 (TLR4/2). Rosenberger et al. have also discovered
the predominant expression of HSP60 in neuronal cells over
microglia and astrocytes in the brain [58]. However, interac-
tion of the CNS neuronal HSP60 and the members of the
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TLR family remains controversial as some studies have sug-
gested that brain neurons activate inflammation through
TLR-3 rather than TLR-2 and TLR-4 [59]. Table 1 shows the
expression of TLR family members in CNS cells (adapted
from [60]).
Moreover, nucleotide-binding oligomerization domain
leucine-rich repeat and pyrin domain-containing 3 (NLRP3)
which is another family of pattern-recognizing receptors has
been identified as a promising receptor for HSP60 [61]. It is
observed that HSP60 can regulate endogenous IL-1β produc-
tion by mitochondrial stress-induced activation of the
NLRP3 inflammasome pathway in the microglia [62]. Later,
Swaroop et al. have corroborated their early findings and
revealed that downregulating HSP60 enables the reduction
of IL-1β production and inflammation in Japanese encepha-
litis virus- (JEV-) infected mice [62]. These findings suggest a
link between mitochondrial stress and neuroinflammation
via HSP60.
4.3. Extracellular HSP60. Even though HSP60 is predomi-
nantly found in mitochondria, recent data suggest that it is
also capable of being localized in the cytosol, nucleus, cell
surface, intercellular vesicles, and extracellular environments
(such as in blood circulation) [63]. HSP60 is secreted from
cells into the extracellular environment through either endo-
plasmic reticulum and the Golgi apparatus or binding with
exosomes and lipid channels [64]. When mitochondria are
under stress, HSP60 is upregulated and transported into the
cellular membrane and Golgi apparatus [63]. At the cell
membrane, HSP60 internalizes through membrane lipid
raft-mediated endocytosis into endosomes [65]. HSP60 can
also encapsulate into exosomes through multivesicular bod-
ies and be transported to neighboring cells [66]. In addition,
free soluble HSP60 molecules can be translocated into the
extracellular environment via Golgi vesicles [67]. Increased
extracellular HSP60 expression in target tissues as well as
body fluids such as blood, saliva, and urine has been docu-
mented in various inflammatory diseases such as cancer, dia-
betes, atherosclerosis, rheumatoid arthritis, insulitis, and
neuroinflammatory diseases [54, 68]. Hence, free or exoso-
mal bound HSP60 could be a promising biomarker for the
diagnosis of inflammation in brain cells. Recent studies have
discovered a clear link between extracellular HSP60 and
immune responses of tissues. However, the mechanism of
secretion of extracellular HSP60 is not clearly understood.
A descriptive study on structural and functional comparison
of intracellular HSP60 and extracellular HSP60 also needs to
be established.
4.4. Neuron-Astrocyte Communication through Exosome in
the CNS. Exosomes are known as a group of vesicles pro-
duced by the cells which are secreted to the extracellular body
fluids such as blood, urine, saliva, and cerebrospinal fluid.
Recent studies have revealed that exosomes play an important
role in cell-to-cell communication in normal and pathological
conditions [69]. Growing evidence also suggested that exo-
somes reflect the functional status of the cell from which it
originates, and it can affect the functions of the cells which it
interacts with. Exosomes permit transport of various proteins
including targeting and fusion proteins, cytoplasmic enzymes,
and molecular stress proteins. Proteins involved with signal
transduction proteins are also known to be associated with
exosomes [66]. Exosomes circulate throughout the body, and
their concentration is elevated in some pathological condi-
tions. In recent years, many studies have discovered that exo-
somes play a crucial role in cellular communication, nerve
regeneration, synaptic function, and immune responses in
the central nervous system. Latest finding has demonstrated
that secretion of exosomes in the central nervous system
depends on glutamatergic activity and calcium influx [70].
Interestingly, exosomes have also been shown to be
involved in the pathogenesis of neuroinflammation. Exosome-
mediated astrocyte-neuron communication has been shown
to be critical for the survival of neurons [71]. Guitart et al. have
discovered that astrocyte-derived exosomes enabled the
transport of prion protein which is an important protective pro-
tein against oxidative stress to neurons [72]. Interestingly,
Morel and coworkers have characterized the neuron-astrocyte
communication pathway revealing that neuron-secreted
microRNA-encapsulated exosomes can modulate GLT1 pro-
tein in astrocytes [73]. It is evident that astrocyte-derived
exosomes can transport misfolded pathogenic proteins and
miRNAs ultimately promote neuroinflammation [74]. Many
novel investigations have identified that neuron-secreted
exosomes are critical factors in spreading neuroinflammation
and neurodegenerative diseases [75].
Recent findings of Pascua-Maestro et al. have shown that
astrocyte-derived exosomes transport apolipoprotein D to
neurons aiding neuronal survival ([76]). Emerging findings
have uncovered that exosomes are involved with the trans-
port of innate immune receptors such as Toll-like receptor
(TLR) 4 and NOD-like receptor 3 (NLRP3) which are
responsible for secreting inflammatory mediators which
leads to neuroinflammation [77]. Astrocytes are also able to
secrete proinflammatory cytokine-loaded exosomes which
stimulate the inflammation in neurons [78].
The most recent studies have focused considerable
attention on the role of exosomes and pathogenesis of diabe-
tes. It is becoming evident that exosomes are involved in the
pathogenesis of diabetic complications through stimulating
inflammation, lowering GLUT4 as well as insulin receptors
[34]. Interestingly, these exosomes can transport abnormal
molecules and microRNA in diabetic patients. In addition,
Table 1: Expression of TLR family members in CNS cells.
Microglia Neuron Astrocyte Oligodendrocyte
TLR 1 + - - -
TLR 2 + - + +
TLR 3 + + + +
TLR 4 + - - -
TLR 5 + - - -
TLR 6 + - - -
TLR 7 + + - -
TLR 8 + + - -
TLR 9 + + + -
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exosomes play a significant role in the treatments of cognitive
impairments in diabetic patients. Nakano and coworkers
have revealed that intracerebroventricular injection of bone
marrow-derived mesenchymal stem cells was able to restore
the cognitive impairments in diabetic mice [79]. Kalani
et al. have also discovered the therapeutic efficacy of miR-
146a-loaded brain endothelial cell-derived exosomes for the
inhibition of gene expression of prion protein in diabetic
db/db mice. These exosomes have achieved significant
improvement in prion protein-induced cognitive impair-
ments in diabetic mice [80].
We propose that neurons might be able to communicate
with astrocytes via exosomal protein such as HSP60 during
cellular stress condition like hyperglycemia. Remarkably,
exosomes have become promising candidates as markers of
inflammation in the central nervous system. Their ability to
be transported through the blood-brain barrier could be
exploited by measuring exosome concentration in cerebro-
spinal fluid and plasma as an indicator of brain inflamma-
tion. This feature of exosome suggests that measurements
of exosomal HSP60 in diabetic patients could also be
exploited to predict neuroinflammation in the diabetic brain.
Therefore, exosomal HSP60 could be a focal point of devel-
oping a biomarker of neuroinflammation in diabetes.
4.5. Studies on the Expression of HSP60 in Peripheral Tissues.
Elevated expression of the HSP60 level in diabetic patients is
well documented with recent studies on saliva and serum eval-
uation of diabetic individuals [81]. Diabetes has been found to
be associated with upregulation of HSP60 via ROS-induced
mitochondrial dysfunction. Hall and Martinus have revealed
that hyperglycemia and oxidative stress are responsible for ele-
vating the expression of HSP60 in human HeLa cells [82].
Their findings have successfully demonstrated that three and
seven days of exposure of HeLa cells to 100mM glucose signif-
icantly increase the ROS production and expression of HSP60
compared to the control group. Moreover, this investigation
has also suggested that upregulation of HSP60 is strongly
related to ROS-mediated processes. Later, Martinus and
Goldsbury have reported that humanmonocyte leukemia cells
(THP-1) grown under hyperglycemic conditions (25mM glu-
cose) are able to release significant HSP60 amount into growth
media than control cells grown under normoglycemic condi-
tion [83]. Furthermore, the conditioned media obtained from
THP-1 cells were able to induce the secretion of TNF-α in
human vascular endothelium cells.
5. Conclusion and Molecular Model Linking
Mitochondrial Stress and
Neuronal Inflammation
HSP60, a molecular stress protein predominantly found in
the mitochondrial matrix, is known to be upregulated and
Inflammatory mediators 
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Figure 1: A model linking mitochondrial stress (via HSP60) to neuroinflammation. Hyperglycemia-induced overproduction of reactive
oxygen species leads to mitochondrial dysfunction in neuron cells resulting in the upregulation of HSP60 expression. Excess HSP60 travels
to the plasma membrane of neuron cell and binds with pattern recognition receptors. Subsequently, activated pattern recognition
receptors initiate inflammatory signaling cascades, stimulate the production of inflammatory mediators, and ultimately lead to
inflammation in neuron cell. Upregulated HSP60 in the neuron can also be secreted into the extracellular environment from neuronal
mitochondria via exosomes. Afterward, extracellular exosomal HSP60 travels to neighboring astrocytes and binds with pattern recognition
receptors on cell membrane of astrocytes, which in turn lead to triggering of an inflammatory response in astrocyte cells, thus
contributing to neuroinflammation. PRR: pattern recognition receptors; HSP60: heat shock protein 60; N: nucleus; M: mitochondria.
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secreted from cells during hyperglycemia-induced mito-
chondrial stress. This extracellular HSP60 is also known
to stimulate inflammation in peripheral vascular environ-
ments (endothelial cells). To date, there are no reports of
hyperglycemia-induced inflammation in the central nervous
system through HSP60-activated inflammatory pathways.
We propose that hyperglycemia-induced upregulation of
HSP60 expression in human neuronal cells may activate
inflammatory pathways by stimulating Toll-like receptors
which are located in the neuronal cell membrane to release
proinflammatory cytokines. Furthermore, we hypothesize
that upregulated HSP60 is secreted into the extracellular
environment from neuronal mitochondria via exosomes.
Moreover, we also suggest that extracellular exosomal
HSP60 could travel to neighboring astrocytes and bind with
Toll-like receptors on the cell membrane of astrocytes, which
in turn would lead to triggering of an inflammatory response
in astrocyte cells (Figure 1).
This potential molecular mechanism linking hyperglyce-
mia to neuroinflammation in diabetes has implications for
developing novel therapeutic approaches for the treatment
of vascular dementia in diabetic patients.
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